Aurobindo Pharma is currently trading at Rs. 516.50, up by 6.45 points or 1.26% from its previous closing of Rs. 510.05 on the BSE.
The scrip opened at Rs. 510.10 and has touched a high and low of Rs. 520.75 and Rs. 508.30 respectively. So far 395664 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 838.00 on 30-Apr-2019 and a 52 week low of Rs. 389.70 on 14-Nov-2019.
Last one week high and low of the scrip stood at Rs. 539.60 and Rs. 491.90 respectively. The current market cap of the company is Rs. 30000.06 crore.
The promoters holding in the company stood at 51.87%, while Institutions and Non-Institutions held 34.60% and 13.53% respectively.
Aurobindo Pharma has received the Establishment Inspection Report (EIR) with Voluntary Action Initiated (VAI) status from the US Food and Drug Administration (USFDA) for its Unit VIII, API manufacturing facility at Gaddapotharam, Hyderabad. The USFDA had inspected company's Unit VIII from October 21, 2019 and October 28, 2019.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments
